Intuitive Surgical (ISRG) Earnings Date & Reports

Key Takeaways

• Second quarter 2026 revenue rose 19% year over year to $2.89 billion, ahead of consensus estimates of about $2.82 billion.
• Non-GAAP diluted earnings per share (EPS, or profit per share) climbed 28% to $2.80, beating analyst expectations of roughly $2.51.
• Total worldwide procedures grew 16%, including 15% growth in da Vinci procedures and 36% growth in Ion procedures.
• The company placed 468 da Vinci surgical systems, up from 395 in the prior-year quarter.
• Full-year 2026 da Vinci procedure growth guidance was reaffirmed at 13.5% to 15.5%, expected near the midpoint.
• Despite the beat, shares fell sharply after hours as U.S. procedure growth slowed to 12%.

Earnings Context and Why It Matters

Intuitive Surgical is the dominant player in robotic-assisted surgery, and its quarterly report is closely watched as a barometer of hospital capital spending and surgical procedure volumes. The company's recurring revenue model, driven by instruments, accessories, and services tied to its installed base of da Vinci and Ion systems, makes procedure growth the single most important metric for investors. Heading into this report, the focus was on whether procedure momentum could hold after a strong first quarter, and how the newer da Vinci 5 platform and Ion lung-biopsy system would contribute. The results carried added weight because Intuitive's premium valuation leaves little room for disappointment.

Reported Results

Intuitive Surgical reported second quarter 2026 revenue of $2.89 billion, a 19% increase from $2.44 billion a year earlier and above the consensus estimate of about $2.82 billion. Recurring revenue rose 19% to $2.47 billion, representing 85% of total revenue. Instruments and accessories revenue grew 18% to $1.73 billion, systems revenue increased 19% to $685 million, and services revenue rose 21% to $472.4 million.

On a GAAP basis (Generally Accepted Accounting Principles), net income attributable to Intuitive was $818.1 million, or $2.29 per diluted share, compared with $658.4 million, or $1.81 per share, in the prior-year quarter. Non-GAAP net income reached $1.0 billion, with non-GAAP diluted EPS of $2.80, up 28% and above the consensus estimate of approximately $2.51. The quarter included a roughly $36 million pre-tax benefit tied to a refund of previously paid tariffs under the IEEPA (International Emergency Economic Powers Act).

Total procedures grew 16% year over year. da Vinci procedures increased 15%, while Ion procedures surged 36% to approximately 48,000. The company placed 468 da Vinci systems, up 18%, including 246 da Vinci 5 systems, and 55 Ion systems. The global installed base reached nearly 13,000 systems, with the da Vinci base up 12% and the Ion base up 21%.

For full-year 2026, Intuitive maintained its forecast for worldwide da Vinci procedure growth of 13.5% to 15.5%, expected near the midpoint, and raised its non-GAAP gross margin outlook to 68% to 69% of revenue, up from 67.5% to 68.5%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trend signals, volatility, and AI-driven analytics. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are monitoring a robotics leader like Intuitive Surgical or scanning an entire industry, the AI Screener can help you narrow the field quickly. Explore the AI Screener to see how it can support your research workflow.

Market Reaction and Investor Sentiment

Despite the headline beat, Intuitive Surgical shares fell sharply after the release. The stock had closed up 3.4% at $402.33 on the day of the report, but declined roughly 10% to 12% in after-hours trading. The pullback reflected investor concern over a slowdown in U.S. da Vinci procedure growth, which decelerated to 12% from 14% in the first quarter. Management attributed part of the moderation to patients deferring elective procedures, citing feedback that changes in patient coverage and insurance premium dynamics, including the expiration of subsidies for Affordable Care Act enhanced premiums, may be affecting when patients seek care. Rising use of GLP-1 (glucagon-like peptide-1) weight-loss medications also continued to weigh on bariatric procedure volumes, which declined in the high single digits during the quarter.

Forward Outlook and Key Factors to Monitor

The most important signal to watch next is whether U.S. da Vinci procedure growth stabilizes or continues to moderate. Management maintained its full-year 2026 procedure growth guidance of 13.5% to 15.5%, implying confidence that demand remains resilient, but the trajectory of deferrable procedures will be closely scrutinized in the third quarter report scheduled for late October.

Investors should also monitor the adoption ramp of the da Vinci 5 platform, which now exceeds 1,700 installed systems and is a key driver of both placements and recurring revenue. Continued strength in Ion procedures, up 36% in the quarter, represents another growth lever as Intuitive expands into diagnostic lung-biopsy and related applications.

On the cost side, the company's raised gross margin outlook of 68% to 69% signals improving profitability, though tariffs and supply-chain dynamics remain variables to track. International markets, where da Vinci procedure growth reached 20%, may provide a buffer against domestic softness, while China and Japan continue to present market-specific pricing and demand considerations. Balanced against these factors, Intuitive's debt-free balance sheet with $8.6 billion in cash and investments provides significant financial flexibility to support continued innovation and shareholder returns.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations